Clinical Trial Update: BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma. [Phase 1]

View source ↗

Summary

A Phase 1 trial testing BC001 with Sintilimab and the XELOX regimen for HER-2 negative advanced/metastatic gastric cancer or gastroesophageal junction adenocarc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• BC001 (BC001)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. | Conditions: Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 1 | Status: RECRUITING